Foundation Medicine has appointed Lisa Ricciardi to the newly created position of senior vice president, corporate and business development. She will be responsible for overseeing the company's biopharmaceutical partnerships as well as corporate and business development activities across the company. Previously, Ricciardi held a number of business development and marketing roles in pharmaceuticals, healthcare services, and finance, including at Pfizer, Essex Woodlands Health Ventures, and Medco Health Solutions. Most recently, she was a consultant to the specialty pharmacy division of DaVita.
Asuragen has appointed Matthew McManus as CEO and president.
McManus was most recently CEO and president of PrimeraDx, and MDx platform developer recently acquired by Qiagen. Prior to this, he was head of Cleveland Clinic Laboratories and chief operating officer of the Pathology and Laboratory Medicine Institute at the Cleveland Clinic. He holds an MD and PhD from the University of Pennsylvania School of Medicine and an MBA from Boston College.
Asuragen also said this week that it has named Darin Leigh as senior vice president of commercial operations and Eric Lindquist as vice president of business development, companion diagnostics.
Prior to joining Asuragen, Leigh was vice president of global commercial operations with Luminex. He also served in strategic marketing and sales roles at Abbott Laboratories. Lindquist has held senior roles in business development, sales, and marketing at HTG, Ventana/Roche, Apocell, Vysis/Abbott, and Veridex.
Exosome Diagnostics has appointed Thomas McLain to be its CEO. McLain most recently was CEO of Vermillion, and previously was CEO at Claro Scientific, and chairman, CEO, and president of Nabi Biopharmaceuticals. McLain replaces James McCullough, who was founding CEO of Exosome.